VerifyNow Aspirin Test

Aspirin: Always The First Choice

Aspirin Response: Significant Impact,

Yet an Overlooked Topic

Aspirin is the most widely used antiplatelet agent in the

world and is the cornerstone of oral antiplatelet therapy,
with all P2Y12 inhibitors being prescribed in conjunction
with this primary antiplatelet agent.
Reports cite up to 25% of patients on aspirin may not
achieve a reduced level of platelet reactivity. Patients
who are not responding adequately to aspirin may be at
significantly increased risk for cardiovascular events. 1,2

As proven in numerous studies, patients who have

high residual platelet reactivity (HRPR) despite aspirin
treatment may be at an increased risk of cardiac events.3,4
Other studies have explored the impact of HRPR in
patients on aspirin and other antiplatelet medications
and suggest that these patients may be at the greatest
risk for recurrent cardiovascular events. 5

N=422, 23.2% HRPR to Aspirin, as identified by VerifyNow Aspirin Test 4,5

Normal Platelet Reactivity

High Platelet Reactivity

100

15

Normal Platelet Reactivity

High Aspirin Platelet Reactivity

High Clopidogrel Platelet Reactivity

Dual Antiplatelet Platelet Reactivity

95
10
90
5
85

80
0

100

200

300

365

Time (days)

100

200

300

Time (days)

Primary Endpoint: composite all-cause death, non-fatal acute myocardial infarction, stent thrombosis and ischemic stroke.

The VerifyNow Solution

In a head to head comparison of 4 platelet function tests
assessing their ability to predict clinical outcomes in patients
on aspirin therapy, only the VerifyNow Aspirin Test and
traditional light transmittance aggregometry correlated to
clinical outcomes.4 Proven in numerous publications, the
VerifyNow Aspirin Test:
Is the technology of choice.
Has validated accuracy, reproducibility and correlation to
clinical outcomes.
Assesses platelet reactivity accurately in response to
aspirin
Is the ONLY platelet reactivity test for patients on aspirin
therapy that can be performed rapidly and easily at
bedside.

365

VerifyNow Aspirin Test

Aspirin binds to the COX-1 enzyme to prevent the conversion
of arachidonic acid to thromboxane A2, which results in platelet
activation. The VerifyNow Aspirin Test utilizes arachidonic acid

as the agonist to measure the antiplatelet effect of aspirin

specifically along this pathway.

Test Purpose:

Measures antiplatelet effect of aspirin

Activation Agonist:

Arachidonic acid

Units of Measurement:

Aspirin Reaction Units (ARU)

Tube type:

Greiner vacuette partial-ll tube (2 ml Fill) 3.2% Sodium Citrate (Greiner Catalog #454322)

Storage Conditions

2 - 25 C

Sample incubation

30 minutes to 4 hours

Time to Result

5 minutes run time

Reference range

Non-Drug (Baseline): 620-672 ARU

Patients with inadequate antiplatelet effect: > 550 ARU
Patients with signicant antiplatelet effect: <550 ARU

Interpreting VerifyNow Aspirin Test Results

Therapeutic Response
ARU values less than 550 are consistent with a patient who is
receiving the therapeutic benefit of aspirin.
Pre-Surgical Screen
Prior to surgery, the VerifyNow Aspirin Test can aid
in guiding clinical decisions whether to discontinue
aspirin therapy or to remain on aspirin to improve graft
patency.6
Medical research suggests that there is patient variability
in response to aspirin.7 Values less than 550 ARU are
reported if the patient is receiving the therapeutic benefit
of aspirin. After aspirin discontinuation, ARUs less than
550 indicate platelets remain inhibited by aspirin.

700
Aspirin Reaction Units (ARU )

Aspirin Reaction Units (ARU) indicate the amount of

thromboxane A2-mediated platelet activation and
aggregation.
ARU is calculated as a function of the rate and extent of
platelet aggregation. Expected values are in the range of
350-700 ARU.
The cut-off to determine if a patient is receiving the
therapeutic benefit of aspirin is 550 ARU.

650

NON-THERAPEUTIC RANGE

600
550
500
450
400
350

References
1. Krasopoulos, G. et al. BMJ 2008 Jan 26;336(7637):195-8.
2. Snoep, JD. et al. Arch Intern Med 2007 Aug 13-27;167(15):1593-9.
3. Chen, WH. et al. Am J Med 2007 Jul;120(7):631-5.
4. Breet, NJ. et al. J Thromb Haemost 2010 Oct;8(10):2140-8.
5. Breet, NJ. et al. Heart 2011 Jun;97(12):983-90.
6. Eagle, KA. et. al. Circulation 2004 Oct 5;110(14):e340-437.
7. Gum, PA. et. al. J Am Coll Cardiol 2001;88:230-235.

www.accumetrics.com | +1.858.643.1600 | Accumetrics International | international@accumetrics.com

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc.,
2011. Accumetrics, Inc. PN:148311.B

THERAPEUTIC RANGE

Post Aspirin Ingestion